Adaptive Biotechnologies (ADPT) vs Immunovant (IMVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunovant (IMVT) has outperformed Adaptive Biotechnologies (ADPT) over the past year, gaining 98.9% versus a gain of 83.1%. Over five years, IMVT leads with a +267.4% price change compared with -21.6% for ADPT. Immunovant is the larger company by market cap ($6.62 billion vs $4.19 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADPT | IMVT |
|---|---|---|
| Share price | $26.28 | $32.04 |
| Market cap | $4.19B | $6.62B |
| 1-day change | -2.30% | -0.22% |
| YTD return | +61.82% | +26.04% |
| 1-year return | +83.14% | +98.88% |
| 5-year return | -21.55% | +267.43% |
| EPS (TTM) | $-0.40 | $-2.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.98M | — |
| Revenue growth (YoY) | +54.77% | — |
| Net income (latest FY) | $-59.50M | $-505.61M |
| Gross margin | 74.24% | — |
| Operating margin | -20.62% | — |
| Net margin | -21.48% | — |
| 52-week high | $30.74 | $45.42 |
| 52-week low | $12.00 | $16.08 |
| Distance from 52-week high | -14.51% | -29.46% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +7.72% | +52.56% |
| Average volume | 2.39M | 1.23M |
| Shares outstanding | 159.60M | 206.55M |
| Employees | 624 | 315 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMVT has outperformed ADPT by 15.7 percentage points over the past year.
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
ADPT vs IMVT FAQ
Which is bigger, Adaptive Biotechnologies or Immunovant?
Immunovant (IMVT) is larger, with a market capitalization of $6.62B compared with $4.19B for Adaptive Biotechnologies (ADPT).
Which stock has performed better over the past year, ADPT or IMVT?
IMVT returned +98.88% over the past 12 months, compared with +83.14% for ADPT (price return, excluding dividends). Past performance does not predict future results.
Are Adaptive Biotechnologies and Immunovant in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.